Literature DB >> 2219707

Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain?

L S Tiley1, P H Brown, B R Cullen.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) encodes a transcriptional trans-activator, termed Tat, that is absolutely required for viral replication in vitro. By analogy to other known transcription factors, it has been suggested that the HIV-1 Tat protein may contain discrete protein domains that determine sequence specificity and transcriptional activation potential. Here, we report the use of site-directed mutagenesis to examine the functional significance of two candidate activation domains within Tat. A 12 amino acid sequence adjacent to the N-terminus of the Tat protein, which includes a proposed acidic amphipathic alpha-helix activation motif, was found to contribute to, but be dispensable for, Tat function in vivo. In contrast, the integrity of a second potential Tat activation motif, centered on a lysine residue at position 41, was found to be essential for Tat function. However, Tat proteins mutated in this area displayed a fully recessive negative phenotype. Therefore, neither of these two regions of the Tat protein appear to be discrete activation domains. We conclude that previous attempts to categorize Tat as a modular transcription factor have not succeeded and suggest that the functional organization of this complex trans-activator remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219707     DOI: 10.1016/0042-6822(90)90354-t

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Transactivation of heterologous promoters by HIV-1 tat.

Authors:  P Han; R Brown; J Barsoum
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

2.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.

Authors:  S J Madore; B R Cullen
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

5.  Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1.

Authors:  A Alonso; T P Cujec; B M Peterlin
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.

Authors:  H Rhim; A P Rice
Journal:  Nucleic Acids Res       Date:  1994-10-25       Impact factor: 16.971

7.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Molecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domain.

Authors:  L Yu; Z Zhang; P M Loewenstein; K Desai; Q Tang; D Mao; J S Symington; M Green
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  The activation region of the Tat protein of human immunodeficiency virus type-1 functions in yeast.

Authors:  T Subramanian; C D'Sa-Eipper; B Elangovan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

10.  Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus.

Authors:  H P Bogerd; R A Fridell; W S Blair; B R Cullen
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.